List of Emerphed drug patents
Emerphed is owned by Nexus Pharms.
Emerphed contains Ephedrine Sulfate.
Emerphed has a total of 5 drug patents out of which 0 drug patents have expired.
Emerphed was authorised for market use on 17 April, 2020.
Emerphed is available in solution;intravenous dosage forms.
Emerphed can be used as use of ephedrine sulfate for treating hypotension.
The generics of Emerphed are possible to be released after 16 May, 2040.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090278 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
| US11241400 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
| US11464752 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
| US11478436 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
| US11571398 | NEXUS PHARMS | NA |
May, 2040
(17 years from now) | |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 17 April, 2020
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION;INTRAVENOUS
EMERPHED family patents
7
United States
1
Japan
1
Korea, Republic of
1
Israel
1
Australia
1
Canada
1
China
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic